Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Assessment of Interleukin 17 in Egyptian Systemic Lupus Erythematosus Patients as a Biomarker in Disease Activity

Author(s): Mervat Behiry, Mary Wadie, Nagwa Abdelghaffar Mohamed, Rania Farid and Hala Ramadan*

Volume 20, Issue 5, 2024

Published on: 30 January, 2024

Page: [534 - 543] Pages: 10

DOI: 10.2174/0115733971282065240123075748

Price: $65

Abstract

Introduction: Systemic lupus erythematosus (SLE) is a chronic idiopathic systemic autoimmune disorder with dysregulation of adaptive and innate immune systems. Interleukin (IL)-17 is the prototypical pro-inflammatory cytokine of T helper 17 (Th17) cells. Therefore, it contributes to the pathogenesis of human SLE.

Aim: The aim of the research paper was the evaluation of IL-17 level as a biomarker in the SLE cohort and its relation to disease activity and analysis of IL-17 concentration in patients with lupus nephritis and non-lupus nephritis.

Methods: The research enrolled 45 SLE patients according to Systemic Lupus International Collaborating Clinics Classification Criteria (SLICC), and age and sex-matched. The patients underwent full history, clinical examination, laboratory investigation, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) calculation.

Results: The mean age ± SD of the participants equaled 32 ± 11 years, and serum IL-17 in SLE cases was statistically significantly high (p < 0.001). No statistically significant correlations were reported between disease activity according to SLEDAI and IL-17. In addition, a statistically significant positive correlation was reported between IL-17 and ESR, and a high statistically significant negative correlation was reported between IL-17 and C3 and C4 (P < 0.001). A statistically significant positive correlation was reported between IL-17 and 24-hour urinary proteins with a Pvalue of 0.01.

Conclusion: SLE cases demonstrated higher levels of serum IL-17, contributing to SLE pathogenesis. However, no statistically significant difference was reported between IL-17 and Lupus nephritis. IL-17 and SLE activity (SLEDAI) did not correlate.

A statistically significant positive relation was reported between IL-17 and 24-hour urinary proteins. Additionally, a high statistically significant negative correlation was reported between IL-17 and C3 and C4.

« Previous Next »
Graphical Abstract

[1]
Maidhof W, Hilas O. Lupus: An overview of the disease and management options. P&T 2012; 37(4): 240-9.
[PMID: 22593636]
[2]
Rönnblom L, Pascual V. The innate immune system in SLE: Type I interferons and dendritic cells. Lupus 2008; 17(5): 394-9.
[http://dx.doi.org/10.1177/0961203308090020] [PMID: 18490415]
[3]
Vaillant AAJ, Qurie A. Interleukin StatPearls. StatPearls Publishing 2020. Internet
[4]
Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol 2010; 7(3): 164-74.
[http://dx.doi.org/10.1038/cmi.2010.21] [PMID: 20383173]
[5]
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64(8): 2677-86.
[http://dx.doi.org/10.1002/art.34473] [PMID: 22553077]
[6]
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377(9767): 721-31.
[http://dx.doi.org/10.1016/S0140-6736(10)61354-2] [PMID: 21296403]
[7]
Robak E, Gerlicz-Kowalczuk Z, Dziankowska-Bartkowiak B, Wozniacka A, Bogaczewicz J. Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. Arch Med Sci 2019; 15(3): 706-12.
[http://dx.doi.org/10.5114/aoms.2019.84738] [PMID: 31110538]
[8]
Assari S, Lankarani MM. Association between stressful life events and depression; intersection of race and gender. J Racial Ethn Health Disparities 2016; 3(2): 349-56.
[http://dx.doi.org/10.1007/s40615-015-0160-5] [PMID: 27271076]
[9]
Mejia-Vilet JM, Rovin BH. Epidemiology and management of lupus nephritis. In: Wallace DJ, Hahn BH, Eds. Dubois’ Lupus Erythematosus and Related Syndromes. (9th ed.). London: Content Repository Only 2019; pp. 727-44.
[http://dx.doi.org/10.1016/B978-0-323-47927-1.00059-1]
[10]
Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 2016; 55(2): 252-62.
[http://dx.doi.org/10.1093/rheumatology/kev311] [PMID: 26342222]
[11]
Robert M, Miossec P. Interleukin-17 and lupus: Enough to be a target? For which patients? Lupus 2020; 29(1): 6-14.
[http://dx.doi.org/10.1177/0961203319891243] [PMID: 31791181]
[12]
Gheita TA, Noor RA, Abualfadl E, et al. Adult systemic lupus erythematosus in Egypt: The nation-wide spectrum of 3661 patients and world-wide standpoint. Lupus 2021; 30(9): 1526-35.
[http://dx.doi.org/10.1177/09612033211014253] [PMID: 33951965]
[13]
Li W, Ye Z, Yin Z, Zhang K. Clinical and immunological characteristics in 552 systemic lupus erythematosus patients in a southern province of China. Int J Rheum Dis 2017; 20(1): 68-75.
[http://dx.doi.org/10.1111/1756-185X.12480] [PMID: 25865002]
[14]
Mostafa A, Abd Allah A, Abd Alwahed S, Hafez R, Hussien S, Bakry R. Interleukin 17 role as a biomarker in Systemic Lupus Erythematosus patients. Sohag Med J 2022; 26(1): 42-50.
[http://dx.doi.org/10.21608/smj.2022.131003.1313]
[15]
Tarazan MA, Tarazan AA. Sohag medical journal interleukin 17 role as a biomarker in systemic lupus. 2022; 25
[16]
Lee MD. Associations between circulating interleukin-17 levels and systemic lupus erythematosus and between interleukin-17 gene polymorphisms and disease susceptibility: A meta- analysis J Rheum Dis 2020; 27(1): 37-44.
[17]
Raymond W, Eilertsen G, Griffiths S, Nossent J. IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. Eur J Rheumatol 2017; 4(1): 29-35.
[http://dx.doi.org/10.5152/eurjrheum.2017.16059] [PMID: 28293450]
[18]
Yin R, Xu R, Ding L, et al. Circulating IL-17 level is positively associated with disease activity in patients with systemic lupus erythematosus: A systematic review and meta-analysis. BioMed Res Int 2021; 2021: 1-12.
[http://dx.doi.org/10.1155/2021/9952463] [PMID: 34337065]
[19]
Elewa EA, Zakaria O, Mohamed EI, Boghdadi G. The role of interleukins 4, 17 and interferon gamma as biomarkers in patients with Systemic Lupus Erythematosus and their correlation with disease activity. Egypt Rheumatol 2014; 36(1): 21-7.
[http://dx.doi.org/10.1016/j.ejr.2013.10.003]
[20]
Richter P, Macovei LA, Mihai IR, Cardoneanu A, Burlui MA, Rezus E. Cytokines in systemic lupus erythematosus—focus on TNF-α and IL-17. Int J Mol Sci 2023; 24(19): 14413.
[http://dx.doi.org/10.3390/ijms241914413] [PMID: 37833861]
[21]
Maher SE, Taha HA, Hozayn WG, et al. Study of balance between T-helper 17/T-regulatory cells in systemic lupus erythematosus and its relation to disease activity. Curr Pediatr Res 2019; 23: 49-55.
[22]
Elbadry Ali, Hassan AH. Study of interleukin-17 and fc gamma receptor in SLE patients and its relation to disease activity and clinical presentation Clinical Science 2023; 27(3): 7-16.
[http://dx.doi.org/10.21608/smj.2023.211392.1392]
[23]
Zhao XF, Pan HF, Yuan H, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37(1): 81-5.
[http://dx.doi.org/10.1007/s11033-009-9533-3] [PMID: 19347604]
[24]
Alunno A, Bartoloni E, Bistoni O, et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: The old and the new. Clin Dev Immunol 2012; 2012: 1-5.
[http://dx.doi.org/10.1155/2012/823085] [PMID: 22761634]
[25]
Radwan N, Hamza M, Ghareeb I, Hisham M. Serum interleukin-17 expression in a group of Egyptian patients with juvenile systemic lupus erythematosus. Egypt J Pediatr Allergy Immunol 2021; 19(2): 97-103.
[http://dx.doi.org/10.21608/ejpa.2021.35761.1011]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy